Bio-Path Holdings is a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company utilizing a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Co.'s primary drug candidate, prexigebersen, which targets growth factor receptor-bound protein 2, initially started the efficacy portion of a Phase 2 clinical trial for untreated acute myeloid leukemia patients. Co.'s second drug candidate, Liposomal Bcl-2, targets the protein Bcl-2, which is responsible for driving cell survival in up to 60% of all cancers. Co.'s third drug candidate, Liposomal STAT3, targets the STAT3 protein.
|
Free BPTH Email Alerts: Get SEC Filing Alerts Get Dividend Alerts |
Strong Buy (4.00 out of 4) 100th percentile
(ranked higher than approx. 100% of all stocks covered)
Analysts' Target Price: BPTH Stock Forecast Based on Zacks ABR data; powered by Xignite |